Because p75NTR has also been implicated in the progression of melanoma, and specifically in those tumors that metastasize to the brain [33,46,77], therapies that target p75NTR, p75NTR downstream effectors, or their ligands may not only be beneficial for malignant glioma, but may target other metastatic diseases. This evidence concerns the gene NGFR and melanoma.